Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Proteus Syndrome”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04980872
What this trial is testing

The Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Merck Sharp & Dohme LLC 60
Not applicableStudy completedNCT04146922
What this trial is testing

Switch to Oral Antibiotics in Gram-negative Bacteremia

Who this might be right for
Escherichia Coli BacteremiaKlebsiella BacteraemiaEnterobacter Bacteraemia+3 more
Hamad Medical Corporation 176
Not applicableLooking for participantsNCT00001403
What this trial is testing

Study of Proteus Syndrome and Related Congenital Disorders

Who this might be right for
Proteus SyndromePIK3CA Related Overgrowth Spectrum
National Human Genome Research Institute (NHGRI) 1,500
Early research (Phase 1)Study completedNCT02594215
What this trial is testing

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

Who this might be right for
Proteus Syndrome
National Human Genome Research Institute (NHGRI) 6
Not applicableStudy completedNCT01369953
What this trial is testing

Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants

Who this might be right for
Coronary Artery DiseaseProteus SyndromeCoffin - Sins Syndrome+2 more
National Human Genome Research Institute (NHGRI) 30
Not applicableStudy completedNCT06542965
What this trial is testing

Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis

Who this might be right for
Proteus Mirabilis InfectionBacteremiaCarbapenem Resistant Bacterial Infection
Dokuz Eylul University 67
Not applicableNo Longer AvailableNCT03317366
What this trial is testing

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

Who this might be right for
Proteus SyndromePIK3CA-Related Overgrowth Spectrum (PROS)Growth Disorders
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Testing effectiveness (Phase 2)Ended earlyNCT03094832
What this trial is testing

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 50
Testing effectiveness (Phase 2)Looking for participantsNCT04316546
What this trial is testing

MK-7075 (Miransertib) in Proteus Syndrome

Who this might be right for
Proteus Syndrome
National Human Genome Research Institute (NHGRI) 45